Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3,776
Change Today +69.00 / 1.86%
Volume 10.6K
As of 10:24 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

evogene ltd (EVGN) Snapshot

Open
$3,797
Previous Close
$3,707
Day High
$3,827
Day Low
$3,755
52 Week High
06/1/14 - $5,976
52 Week Low
01/25/15 - $3,113
Market Cap
957.6M
Average Volume 10 Days
16.2K
EPS TTM
$-0.62
Shares Outstanding
25.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOGENE LTD (EVGN)

Related News

No related news articles were found.

evogene ltd (EVGN) Related Businessweek News

No Related Businessweek News Found

evogene ltd (EVGN) Details

Evogene Ltd. operates as a plant genomics company that uses a technology infrastructure to enhance seed traits underlying crop productivity. The company operates in two segments, Evogene and Evofuel. The Evogene segment develops technologies to enhance plant performance through seed traits and ag-chemicals. Its seed trait operation utilizes to address yield and abiotic stress and biotic stress traits through the genetic modification or breeding of seeds; and ag-chemical operations utilize to develop novel crop protection and crop enhancement products, including herbicides. The Evofuel segment develops species of the castor bean plant for second generation feedstock for use in the alternative fuel industry, primarily biodiesel and biojet. Its products focus on various crops comprising corn, soybean, wheat, rice, and cotton. Evogene Ltd. has strategic collaborations with agricultural companies primarily to develop traits for yield and abiotic stress tolerance, such as enhanced tolerance to drought, heat, and salinity; and biotic stress resistance, including resistance to disease, pests, and insects. The company was founded in 1999 and is headquartered in Rehovot, Israel.

207 Employees
Last Reported Date: 04/30/15
Founded in 1999

evogene ltd (EVGN) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $436.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $245.0K
Executive Vice President of Technology Infras...
Total Annual Compensation: $252.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $244.0K
Executive Vice President of Strategy and Busi...
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2014.

evogene ltd (EVGN) Key Developments

Evogene Ltd. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015

Evogene Ltd. announced unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $2,701,000 against $3,857,000 a year ago. Net loss was $3,409,000 against $2,337,000 a year ago. Basic and diluted loss per share was $0.13 against $0.094 a year ago. Net cash used in operating activities was $2,572,000 against $3,223,000 a year ago. Purchase of property, plant and equipment were $553,000 against $303,000 a year ago. The decline in revenue was primarily related to the previously announced amendment to the company’s Bayer collaboration work plan. Operating Loss was $4.1 million, compared to an operating loss of $2.6 million for the same period in 2014. This increase is mainly attributable to the decrease in revenues from research and development payments, as well as the increase in self-funded research and development expenses, and certain other operating expenses.

Evogene Ltd. to Report Q1, 2015 Results on May 19, 2015

Evogene Ltd. announced that they will report Q1, 2015 results on May 19, 2015

Evogene Ltd., Q1 2015 Earnings Call, May 19, 2015

Evogene Ltd., Q1 2015 Earnings Call, May 19, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVGN:IT 3,776.00 +69.00

EVGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVGN.
View Industry Companies
 

Industry Analysis

EVGN

Industry Average

Valuation EVGN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOGENE LTD, please visit www.evogene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.